多发性骨髓瘤与miRNAs的研究进展

Research progress on multiple myeloma and MicroRNAs (miRNAs)

ES评分 0

DOI 10.12208/j.ijcr.20250458
刊名
International Journal of Clinical Research
年,卷(期) 2025, 9(9)
作者
作者单位

1 延边大学附属医院血液科 吉林延吉 2 延边大学 吉林延吉

摘要
多发性骨髓瘤(MM)是一种复杂的骨髓浆细胞恶性增殖性疾病,其临床表现多样且预后不佳。近年来,microRNA(miRNAs)作为重要的非编码调控分子,在MM的发病机制、疾病进展、药物耐药及预后评估中显示出关键作用。本文综述了近十年来MM相关miRNAs的研究进展,重点分析了miRNAs在MM病理机制中的作用,并探讨了其在疾病的诊断、预后评估及靶向治疗中的应用潜力以期为MM的早期诊断和个体化治疗提供新的思路和策略。
Abstract
Multiple myeloma (MM) is a complex malignant proliferative disease of bone marrow plasma cells, characterized by diverse clinical manifestations and poor prognosis. In recent years, microRNAs (miRNAs), as important non-coding regulatory molecules, have been shown to play a crucial role in the pathogenesis, disease progression, drug resistance, and prognostic evaluation of MM. This article reviews the research progress of MM-related miRNAs over the past decade, focuses on analyzing the role of miRNAs in the pathological mechanism of MM, and explores their application potential in disease diagnosis, prognostic evaluation, and targeted therapy, aiming to provide new ideas and strategies for the early diagnosis and individualized treatment of MM.
关键词
多发性骨髓瘤;miRNAs;诊断标志物;药物耐药;骨髓微环境
KeyWord
Multiple myeloma; miRNAs; Diagnostic biomarkers; Drug resistance; Bone marrow microenviron-ment
基金项目
页码 162-165
  • 参考文献
  • 相关文献
  • 引用本文

刘萌萌, 王益帆, 赵锡奇. 多发性骨髓瘤与miRNAs的研究进展 [J]. 国际临床研究杂志. 2025; 9; (9). 162 - 165.

  • 文献评论

相关学者

相关机构